Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupNeuro-OncologyThoracic TumorsDiseaseLung Carcinoma, Non-Small CellMalignant MeningitisSubgroupEGFR activating mutationICD10C34.-C79.3MeSHMeningeal CarcinomatosisSequencePEME50/DEXA5, Malignant Meningitis, C1 (PID2529) -|- C2 (PID2530) -|- C3+ (PID2531)ChemotherapyChemo-substanceDexamethasonePemetrexedChemo-substanceDexamethasonePemetrexedChemo-substanceDexamethasonePemetrexedChemo-substanceDexamethasonePemetrexedNo. Substances2 RadiotherapySupportive therapySupportive substanceCyanocobalaminFolic acidGranisetronSupportive substanceCyanocobalaminFolic acidGranisetronSupportive substanceCyanocobalaminFolic acidGranisetronSupportive substanceCyanocobalaminFolic acidGranisetronNo. Substances3Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksEmetogenicityNeurotoxicityNeutropenia only studiesPublicationAuthorFan CDiseaseMeningeosis neoplastica bei NSCLC, EGFR+, nach Vortherapie mit TKI, ECOG 1-3OriginThe Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of ChinaProtocols in Revision 3 protocols foundProtocols under revision.Pemetrexed 50 / Dexamethasone 5, intrathecal, Malignant Meningitis, cycle 1 (PID2529 V1.0)Pemetrexed 50 / Dexamethasone 5, intrathecal, Malignant Meningitis, cycle 2 (PID2530 V1.0)Pemetrexed 50 / Dexamethasone 5, intrathecal, Malignant Meningitis, cycle 3+ (PID2531 V1.0)
